Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology

May 22, 2022

The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.

The Top 5 Biosimilar Articles for the Week of May 16

May 20, 2022

Eye on Pharma: Similis Bio Launch, Biocon Biologics Sets Sights on Malaysian Biosimilar Market

May 19, 2022

Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars

May 18, 2022

Teva’s Lucentis Biosimilar Gains UK Approval

May 17, 2022

Dr Sonia Oskouei Describes the Need for More Biosimilar Education for Ophthalmologists

May 8th 2022

By Skylar Jeremias

Video

Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.

Amgen Biosimilars See Increased Sales as Reference Product Sales Erode

May 7th 2022

By Skylar Jeremias

Article

Amgen’s earnings report for the first quarter of 2022 reveals that as some of its biosimilars experienced increased sales, its sales for reference products that are facing biosimilar competition decreased.

Coherus Biosciences Terminates Deal With Innovent for Avastin Biosimilar

May 6th 2022

By Skylar Jeremias

Article

During the Coherus Biosciences earnings call, the company announced that it was terminating its licensing agreement with Innovent Biologics for Byvasda, a bevacizumab biosimilar candidate referencing Avastin.

The Top 5 Biosimilar Articles for the Week of May 2

May 6th 2022

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of May 2, 2022.

Given Public Concerns, Canadian Policy Makers Should Be Cautious When Making New Biosimilar Policies

May 5th 2022

By Skylar Jeremias

Article

A report on biosimilar uptake and existing policies signals that policy makers should proceed with caution when establishing new policies to boost biosimilar utilization and savings, as many patients and providers still have concerns on their usage.

Medicare Policies Must Fix Cost Sharing Under Part D, Expert Writes

May 4th 2022

By Mary Caffrey

Article

Stacie B. Dusetzina, PhD, is the Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center, and a member of the editorial board for The American Journal of Managed Care®.

Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions

May 4th 2022

By Skylar Jeremias

Video

The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.

The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei

May 3rd 2022

By Laura Joszt

Article

The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.

Opinion: Efforts to Improve Biosimilars Education Are a Start, but Payer Policies Must Catch Up

May 2nd 2022

By Mike Gladstone

Article

Despite improvements in biosimilar education efforts for future health care professionals, payer policies need a major revamp to ensure that biosimilar use is encouraged, according to Pfizer's Mike Gladstone.

Dr Eric Tichy Details Why More State Biosimilar Bills Are Needed

May 1st 2022

By Skylar Jeremias

Video

Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.